The rationale for a combination DDR inhibitory strategy in glioblastoma is also supported by the work of Signore and colleagues, who performed a simultaneous multipathway approach with subsequent reverse‐phase protein microarrays and kinase inhibitor library screening to identify dual inhibition of CHK1 and PDK1, resulted in profound retardation of GSC growth in both in vitro and in vivo (subcutaneous and intracranial mouse) models [182]. The gene discussed is CHEK1; the disease is glioblastoma.